223 related articles for article (PubMed ID: 38543739)
1. The NDV-MLS as an Immunotherapeutic Strategy for Breast Cancer: Proof of Concept in Female Companion Dogs with Spontaneous Mammary Cancer.
Sánchez D; Cesarman-Maus G; Romero L; Sánchez-Verin R; Vail D; Guadarrama M; Pelayo R; Sarmiento-Silva RE; Lizano M
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543739
[TBL] [Abstract][Full Text] [Related]
2. Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.
Sánchez D; Pelayo R; Medina LA; Vadillo E; Sánchez R; Núñez L; Cesarman-Maus G; Sarmiento-Silva RE
Viruses; 2015 Dec; 8(1):. PubMed ID: 26703717
[TBL] [Abstract][Full Text] [Related]
3. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy of oncolytic Newcastle disease virus and rhizomes extract of Rheum ribes enhances cancer virotherapy in vitro and in vivo.
Al-Shammari AM; Jalill RDA; Hussein MF
Mol Biol Rep; 2020 Mar; 47(3):1691-1702. PubMed ID: 31970625
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic effect of Newcastle disease virus is attributed to interferon regulation in canine mammary cancer cell lines.
Santos MR; Xavier PLP; Pires PRL; Rochetti AL; Rosim DF; Scagion GP; de Campos Zuccari DAP; Munir M; Ferreira HL; Fukumasu H
Vet Comp Oncol; 2021 Sep; 19(3):593-601. PubMed ID: 33871162
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment.
Keshavarz M; Ebrahimzadeh MS; Miri SM; Dianat-Moghadam H; Ghorbanhosseini SS; Mohebbi SR; Keyvani H; Ghaemi A
Virol J; 2020 May; 17(1):64. PubMed ID: 32370750
[TBL] [Abstract][Full Text] [Related]
8. Newcastle disease virus LaSota strain induces apoptosis and activates the TNFα/NF-κB pathway in canine mammary carcinoma cells.
Wang J; Li M; Li M
Vet Comp Oncol; 2023 Sep; 21(3):520-532. PubMed ID: 37282822
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model.
Yurchenko KS; Glushchenko AV; Gulyaeva MA; Bi Y; Chen J; Shi W; Adamenko LS; Shestopalov AM
Viruses; 2021 Mar; 13(4):. PubMed ID: 33806229
[TBL] [Abstract][Full Text] [Related]
10. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
11. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
12. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
13. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Newcastle disease virus effects on immune response - a new issue in cancer treatment.
Kooti W; Esmaeili HGG; Farzanehpour M; Dorostkar R; Jalali Kondori B; Bolandian M
Klin Onkol; 2023; 36(2):124-129. PubMed ID: 37072246
[TBL] [Abstract][Full Text] [Related]
15. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
Zamarin D; Holmgaard RB; Subudhi SK; Park JS; Mansour M; Palese P; Merghoub T; Wolchok JD; Allison JP
Sci Transl Med; 2014 Mar; 6(226):226ra32. PubMed ID: 24598590
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.
Zamarin D; Palese P
Future Microbiol; 2012 Mar; 7(3):347-67. PubMed ID: 22393889
[TBL] [Abstract][Full Text] [Related]
17. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma.
Cuoco JA; Rogers CM; Mittal S
Neurosurg Focus; 2021 Feb; 50(2):E8. PubMed ID: 33524945
[TBL] [Abstract][Full Text] [Related]
18. Newcastle disease virus as an oncolytic agent.
Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Newcastle disease virus induced degradation of YAP through E3 ubiquitin ligase PRKN to exacerbate ferroptosis in tumor cells.
Sun Y; Tang L; Kan X; Tan L; Song C; Qiu X; Liao Y; Nair V; Ding C; Liu X; Sun Y
J Virol; 2024 Mar; 98(3):e0189723. PubMed ID: 38411946
[TBL] [Abstract][Full Text] [Related]
20. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
Meng Q; He J; Zhong L; Zhao Y
Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
